Ratings by Rothschild Redburn (Jamie Clark)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/17/2026 | ICON plc | ICLR | Downgrade | Neutral (Buy) |
80.08 (161.40) |
101.55% | Details | |
| 11/21/2025 | Certara Inc. | CERT | New Coverage | Buy (N/A) |
8.29 (8.10) |
-2.29% | Details | |
| 9/15/2025 | West Pharmaceutical | WST | New Coverage | Buy (N/A) |
263.74 (338.65) |
28.4% | Details | |
| 9/3/2025 | Iconix Brand | ICON | Upgrade | Buy (Neutral) |
1.92 (0.98) |
-48.96% | Details | |
| 9/3/2025 | Medpace | MEDP | Downgrade | Neutral (Buy) |
475.51 (583.21) |
22.65% | Details | |
| 9/3/2025 | ICON plc | ICLR | Upgrade | Buy (Neutral) |
177.94 (80.08) |
-55% | Details | |
| 5/23/2025 | Charles River Labs | CRL | Upgrade | Buy (Neutral) |
134.98 (282.34) |
109.17% | Details | |
| 4/2/2025 | Quest Diagnostics | DGX | New Coverage | Buy (N/A) |
169.20 (236.22) |
39.61% | Details | |
| 4/2/2025 | Laboratory Corporation of America | LH | New Coverage | Buy (N/A) |
232.74 (327.61) |
40.76% | Details | |
| 3/3/2025 | Charles River Labs | CRL | Upgrade | Neutral (Sell) |
164.88 (134.98) |
-18.13% | Details |
